Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q3 FY20 Earnings Presentation
21 slides from Dr. Lal Pathlabs's earnings presentation, Feb 3, 2020
Slide 1: Exchange filing cover letter for Q3 & 9M FY20 presentation
February 3, 2020 The National Stock Exchange of India Limited The Bombay Stock Exchange Limited Exchange Plaza Phiroze Jeejeeboy Towers Sandra Kurla Complex, Sandra (E) Dalal Street, Mumbai - 400051 Mumbai - 400001 Subject: Investors Presentation on Unaudited Financial Results (Standalone and Consol
Slide 2: Q3 & 9M FY20 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q3 & 9M FY20 Results Presentation February 3, 2020
Slide 3: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the “Company”) for use in presentat
Slide 4: Q3 FY20 Snapshot
Q3 FY20 Snapshot 12.1% 13.5% 19.1% INR 327.9 Cr INR 80.1 Cr INR 54.9 Cr Revenues Normalised EBITDA* PAT 11.3% 13.7% ~4.8 mn ~11.6 mn Patients Tested Samples Processed * Excluding Ind AS 116 impact 3
Slide 5: Table of Contents
Table of Contents Dr. Lal PathLabs – At a Glance 5 Overview of Dr. Lal PathLabs 6 Key Performance Highlights 7 Financials 8 Financial Highlights 9 Operating Highlights 11 Management Commentary 12 Vibrant Outlook 13 Corporate Overview 14 Shareholding 18 Contact Us 19 DISCLAIMER: This presentation may
Slide 6: Dr. Lal PathLabs – At a Glance
Dr. Lal PathLabs – At a Glance 15% 14% Zero Professionally managed operations; 7 decades of experience in the world of NO. 1 3 Year Revenue 3-Year PAT Net Debt BRANDED diagnostics CAGR CAGR NATIONAL 59% Well diversified outside home market of ‘Delhi NCR’ DIAGNOSTICS ~70% CHAIN WITH Revenue Contribut
Slide 7: Overview of Dr. Lal PathLabs
Overview of Dr. Lal PathLabs Established brand Pan-India integrated Varied Offerings Unique and successful coverage operating model 200 clinical labs (including National Reference Lab at Catalogue of 459 test panels, Scalable model integrated Established consumer Delhi and Regional Reference 2,489 p
Slide 8: Key Performance Highlights
Key Performance Highlights In Q3 FY20, patient volumes increased by 11.3% led by higher growth in the Rest of India market, further supported by stable momentum in the other regions During Q3 FY20: • Revenues increased by 12.1% Y-o-Y at Rs. 327.9 crore • Number of patients tested stood at 4.8 millio
Slide 9: Financials
Financials YTD YTD YTD Q3 FY20 Q3 FY20 Q3 FY19 Gr % Gr % Gr % Gr % Q3 FY20 Q3 FY20 Q3 FY19 Particulars (Rs. Cr.) (With IND- (W/O IND- (W/O IND- (With IND (W/O IND- (With IND- (W/O IND- (W/O IND- (With IND (W/O IND- AS 116) AS 116) AS 116) AS 116) AS 116) AS 116) AS 116) AS 116) AS 116) AS 116) Reven
Slide 10: Financial Highlights
Financial Highlights All figures in Rs. Crore 292.5 327.9 Revenue growth in Q3 FY20 stood at 12.1%, at Rs. 327.9 crore. This was contributed by: Revenue • Continued momentum in volumes, which grew by 11.3% and • Higher growth in tests per patient from 2.38 to 2.43 Realisation per patient in Q3 F
Slide 11: Financial Highlights
Financial Highlights All figures in Rs. Crore 67.9 73.4 PBT for Q3 FY20 came in at Rs. 73.4 crore vs. Rs. 67.9 crore in the corresponding quarter of last year, representing a growth of 8.1% PBT Q3 FY20 PBT margin stood at 22.4%, as against 23.2% in the same period of last year Q3 FY19 Q3 FY20
Slide 12: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs 189 193 200 2,569 6,426 2,153 5,021 5,624 1,759 FY17 FY18 FY19 FY17 FY18 FY19 FY17 FY18 FY19 No. of Patients No. of Samples 17.6 41.8 15.2 34.7 13.3 29.3 15.0 36.5 FY17 FY18 FY19 9M FY20 FY17 FY18 FY19 9M FY20 11
Slide 13: Management Commentary
Management Commentary Commenting on the results announcement, Dr. Arvind Lal - Chairman and Managing Director said: “We continue to demonstrate healthy performance quarter-on-quarter led by our focus on basic fundamentals of business and aspiration to maintain high levels of quality and scale. There
Slide 14: Vibrant Outlook
Vibrant Outlook Strongly develop Rest of India geographies, through Kolkata National Laboratory and cluster city approach for attractive markets Target to grow Evaluate best fit inorganic Deeper Penetration within the ahead opportunities North, East & Central Indian of the markets industry Higher co
Slide 15: Leveraging digital to make life easier for patient
Leveraging digital to make life easier for patient Digital Lab e-Commerce Mobile app • Self Registration Kiosk for • Online test / health package • Test booking, view and patients booking download current and • Integrated payment gateway • Online payment, order related historical test reports for on
Slide 16: Corporate Overview
Corporate Overview DLPL Strategy for future growth Experienced Management team 15
Slide 17: DLPL Strategy for future growth
DLPL Strategy for future growth 1 2 Strengthen Expansion in Existing Offering Operations 4 3 Expand management of Geographic hospital based expansion and clinical laboratories 16
Slide 18: DLPL Strategy for future growth
DLPL Strategy for future growth Expand management of hospital Strengthen Existing Operations Expansion in Offering Geographic expansion based and clinical laboratories Boosting quality & reliability Improve breadth of Tap incremental contracts for Focus city approach standards diagnostic testing in
Slide 19: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Ved Prakash Goel Bharath Uppiliappan Whole-time Director and Chief Chairman and Managing Director Whole-time Director Chief Financial Officer CEO India Business Executive Officer Shankha Banerjee Munender Soper
Slide 20: Shareholding as of 31st December, 2019
Shareholding as of 31st December, 2019 20.3% FIIs 13.4% 56.8% Others Promoter and Promoter Group 9.5% Mutual Funds* *Mutual Funds includes Alternate Investment Funds as well 19
Slide 21: Contact Us
Contact Us About Dr. Lal PathLabs Limited (DLPL) Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests